Published in J Clin Invest on July 02, 2012
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
New players in haemostasis and thrombosis. Thromb Haemost (2014) 1.29
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood (2013) 1.19
Fluid Mechanics of Blood Clot Formation. Annu Rev Fluid Mech (2015) 1.13
Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol (2013) 1.12
Dynamics of blood flow and thrombus formation in a multi-bypass microfluidic ladder network. Cell Mol Bioeng (2016) 0.84
Mechanisms of thrombogenesis in polycythemia vera. Blood Rev (2014) 0.81
Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients. Plast Reconstr Surg Glob Open (2015) 0.80
Antithrombotics in heart failure. Croat Med J (2014) 0.80
Endothelial cell control of thrombosis. BMC Cardiovasc Disord (2015) 0.80
Strengths and weaknesses of a new mouse model of thrombosis induced by inferior vena cava stenosis: communication from the SSC of the ISTH. J Thromb Haemost (2014) 0.80
Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol (2013) 0.78
Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol (2015) 0.77
Microparticles as Biomarkers of Blood Coagulation in Cancer. Biomark Cancer (2015) 0.77
Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood (2016) 0.76
Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke. JCI Insight (2016) 0.76
Swine Model of Thrombotic Caval Occlusion Created by Autologous Thrombus Injection with Assistance of Intra-caval Net Knitting. Sci Rep (2015) 0.75
Platelet-independent adhesion of calcium-loaded erythrocytes to von Willebrand factor. PLoS One (2017) 0.75
Platelet full length TFPI-α in healthy volunteers is not affected by sex or hormonal use. PLoS One (2017) 0.75
Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Med (2016) 0.75
Do pregnant women have a higher risk for venous thromboembolism following air travel? Adv Biomed Res (2015) 0.75
Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep (2017) 0.75
Streptokinase production from Streptococcus dysgalactiae subsp. equisimilis SK-6 in the presence of surfactants, growth factors and trace elements. 3 Biotech (2014) 0.75
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. Menopause (2016) 0.75
Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study. Theranostics (2015) 0.75
Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution. J Thromb Haemost (2014) 0.75
Simulated thrombin responses in venous valves. J Vasc Surg Venous Lymphat Disord (2015) 0.75
A Mathematical Model of Venous Thrombosis Initiation. Biophys J (2016) 0.75
Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hemostatic factor levels in postmenopausal women. J Thromb Haemost (2016) 0.75
Localization of Short-Chain Polyphosphate Enhances its Ability to Clot Flowing Blood Plasma. Sci Rep (2017) 0.75
Assessment of Venous Thrombosis in Animal Models. Arterioscler Thromb Vasc Biol (2015) 0.75
Mouse models of deep vein thrombosis. Gefasschirurgie (2016) 0.75
Exploring potential anticoagulant drug formulations using thrombin generation test. Biochem Biophys Rep (2015) 0.75
Blockade of the dissociation of NMMHC IIA from TNFR2 by D39, a saponin from Liriope muscari, suppresses tissue factor expression and venous thrombosis. Br J Pharmacol (2017) 0.75
Lipid levels and risk of venous thrombosis: results from the MEGA-study. Eur J Epidemiol (2017) 0.75
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl) (2017) 0.75
Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 17.18
Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med (1998) 9.43
Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet (1960) 7.96
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 5.69
Mechanisms of thrombus formation. N Engl J Med (2008) 4.67
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell (2009) 4.50
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med (2004) 4.38
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med (2003) 3.61
Triggers, targets and treatments for thrombosis. Nature (2008) 3.51
Deep vein thrombosis. Lancet (2005) 3.43
The iliac compression syndrome. Br J Surg (1965) 3.40
Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost (2012) 3.39
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 3.36
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
The protein C pathway. Chest (2003) 3.14
Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A (2006) 3.09
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol (2004) 3.03
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet (2006) 2.94
von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82
Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest (1997) 2.75
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring) (2007) 2.68
Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood (2010) 2.66
Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med (1998) 2.58
The regulation of natural anticoagulant pathways. Science (1987) 2.58
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature (1992) 2.48
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol (2003) 2.33
Prediction of venous thromboembolism in cancer patients. Blood (2010) 2.31
Microparticles in hemostasis and thrombosis. Circ Res (2011) 2.26
Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost (2008) 2.24
Vascular-bed--specific hemostasis and hypercoagulable states. N Engl J Med (1999) 2.21
The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest (1997) 2.18
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood (2004) 2.16
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 2.05
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res (2009) 2.04
Valves of the deep venous system: an overlooked risk factor. Blood (2009) 1.99
Arterial thrombosis--insidious, unpredictable and deadly. Nat Med (2011) 1.96
The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 1.96
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol (2008) 1.93
The role of von Willebrand factor in thrombus formation. Thromb Res (2007) 1.85
Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest (1996) 1.81
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost (2003) 1.80
Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest (1987) 1.74
Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol (2009) 1.73
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol (2011) 1.65
The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost (2007) 1.60
Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol (2011) 1.59
Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med (2009) 1.58
Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol (2011) 1.57
Genetics of venous thrombosis. J Thromb Haemost (2009) 1.54
Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol (2005) 1.53
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest (2012) 1.51
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
New anticoagulants. Circulation (2010) 1.48
Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.46
Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol (2009) 1.46
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
May-Thurner syndrome: case report and review of the literature involving modern endovascular therapy. Vascular (2009) 1.41
Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions. Arterioscler Thromb Vasc Biol (2011) 1.39
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Haemostatic changes in pregnancy. Best Pract Res Clin Haematol (2003) 1.39
Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol (2010) 1.34
Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol (2012) 1.33
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol (2010) 1.31
The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med (2004) 1.31
The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg (1981) 1.27
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med (2010) 1.27
Tissue factor pathway inhibitor. Thromb Haemost (1995) 1.25
Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Mol Dis (2006) 1.24
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost (2008) 1.22
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
Venous thromboembolism and prognosis in cancer. Thromb Res (2010) 1.16
Venous thrombosis in the elderly. J Thromb Haemost (2007) 1.15
Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol (2011) 1.15
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost (2008) 1.15
Obesity and venous thrombosis: a review. Semin Thromb Hemost (2011) 1.12
Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. Curr Pharm Des (2009) 1.10
A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol (2012) 1.08
Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol (1997) 1.08
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol (1997) 1.07
Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol (2011) 1.03
The link between vascular features and thrombosis. Annu Rev Physiol (2011) 0.99
Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis (2000) 0.98
Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol (2004) 0.95
Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res (2009) 0.95